Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison studyLulu Liu, Lei Wang, Yiling Ding, Qilin Zhang, Yamin Shu
6 March 2025
Evaluating the costs, work patterns and efficiency (CORE) of comprehensive primary healthcare (CPHC) in India (The CPHC CORE study): a top-down micro-costing study protocolPrakash Singh, Ajay Trakroo, Shweta Sharda, Praween Agrawal, Sitanshu S Kar, Beena Joshi, Surya Bali, Sudip Bhattacharya, Kuldeep Singh, Sandra Albert, Aarti Goyal, Sandeep Sharma, Arun K Aggarwal, Atul Kotwal, Luigi D’AquinoSee the full list of authors
5 March 2025
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in ChinaLiangxiao Wang, Na Lv, Yuan Gao, Chunyan Yan, Xuechen Huo, Ruigang Diao
3 March 2025
Intravenous lidocaine for gut function recovery in colonic surgery: a health economic evaluation of the ALLEGRO randomised clinical trialMarek Atter, Andrew Stoddart, Seonaidh Cotton, Thenmalar Vadiveloo, Karen Innes, Angie Balfour, Robert Arnott, Lorna Aucott, Zoe Batham, Irwin Foo, Graeme MacLennan, Susan Nimmo, Doug Speake, John Norrie, Hugh Paterson
25 February 2025
Estimating the indirect costs associated with adenocarcinoma or squamous cell carcinoma of the oesophagus in Switzerland: evidence from a cross-sectional surveySandro T Stoffel, Arjun Bhadhuri, Paola Salari, Dieter Koeberle, Thibaud Koessler, Alexander Siebenhüner, Letizia Deantonio, Miklos Pless, Tim Kahl, Andreas Wicki, César Oniangue-Ndza, Matthias Schwenkglenks
22 February 2025
Health valuation protocol for dual discrete choice experiment (dual-DCE) surveys to estimate the effects of different scenarios and attributes on main effectsBenjamin Matthew Craig
22 February 2025
Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantationDan Xie, Peng-Fei Zhang
19 February 2025
National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modellingKimberly Badal, James Staib, Jeffrey A. Tice, Mi-Ok Kim, Martin Eklund, Leslie Wilson, Stacey Dacosta Byfield, Kierstin Catlett, Liz Maffey, Rashna Soonavala, Yiwey Shieh, Laura J. Esserman
17 February 2025
Evidence quality and uncertainties considered in appraisal documents of drugs for rare diseases in England and Germany: a data extraction protocolLea Wiedmann, Ellen Nolte, John Cairns
16 February 2025
A model based cost-utility analysis of Embedding referral to structured self-management education into standard practice (Embedding) compared to usual care for people with type 2 diabetes diagnosis in the last 12 months in EnglandDaniel John Pollard, Anju Keetharuth, Alan Brennan, Danielle H Bodicoat, Agnieszka Glab, Michelle Hadjiconstantinou, Joesph P Mensa, Alison Northern, Melanie J Davies
11 February 2025
